[ad_1]
On Thursday, a vaccine advisory group to the Food and Drug Administration (FDA), the U.S. government agency for food and drug safety, recommended that the FDA itself authorize the use of the vaccine from Pfizer-BioNTech. The FDA will very likely give its final approval in a few days, on Saturday, according to sources cited by New York Times – allowing the start of the coronavirus vaccination campaign in the United States. The initial availability of vaccines will be 6.4 million doses.
On Wednesday, the FDA released a series of documents reporting that the Pfizer-BioNTech vaccine provides “marked protection” against the coronavirus. The vaccine was recently licensed in the UK, where the first vaccinations (albeit in a limited number of people) began on Tuesday, and in November the two companies, Pfizer and BioNTech, had reported 95 percent effectiveness of their solution when receiving the second dose of the vaccine, according to data from the last clinical trial (out of 3) carried out on about 44 thousand volunteers.
[ad_2]
